钇90经动脉放射栓塞治疗肝细胞癌研究进展

Research progress on yttrium-90 transarterial radioembolization for hepatocellular carcinoma

摘要

肝细胞癌(hepatocellular carcinoma,HCC)发病隐匿,早期诊断困难,并且疾病进展快,预后差,已成为全球性的重大健康威胁。钇90经动脉放射栓塞(transarterial radioembolization,TARE)是一种新兴的肝癌局部治疗方式,尽管在我国大陆临床应用时间尚短,但已有研究表明其临床应用前景良好。本文通过查阅文献资料,对TARE治疗HCC患者的有效性、安全性进行综述,以期为临床用药提供参考。

Abstract

Hepatocellular carcinoma (HCC) is characterized by its insidious onset, difficulty in early diagnosis, rapid disease progression, and poor prognosis, making it a major global health threat. Yttrium-90 transarterial radioembolization (TARE) is an emerging local treatment for liver cancer. Although its clinical application in mainland China is relatively recent, studies have shown promising clinical prospects. This article reviews the efficacy and safety of TARE in the treatment of HCC patients by reviewing literature, aiming to provide reference for clinical medication.

关键词

肝细胞癌 / 钇90 / 选择性内放射治疗 / 经动脉放射栓塞 / 介入治疗

Key words

hepatocellular carcinoma / yttrium 90 / selective internal radiation therapy / transarterial radioembolization / interventional therapy

[1] SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 李广欣, 张钰, 杨艳美, 等. 真实世界中仑伐替尼治疗不可切除晚期肝细胞癌的效果及安全性观察[J]. 临床肝胆病杂志, 2020, 36(10): 2266-2269.
[3] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)原发性肝癌诊疗指南-2024[M]. 北京: 人民卫生出版社, 2024.
[4] VILGRAIN V, PEREIRA H, ASSENAT E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1624-1636.
[5] 张涵, 刘四斌. 钇90微球内放射治疗在肝恶性肿瘤的应用进展[J]. 医学理论与实践, 2023, 36(12): 2014-2016.
[6] ARIEL IM. Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (y90 radiating microspheres)[J]. Ann Surg, 1965, 162(2): 267-278.
[7] 马婧嶔, 张林泓, 杨敏捷, 等. 钇-90选择性内放射治疗肝癌的过去、现在与未来[J]. 中国临床医学, 2025, 32(1): 3-8.
[8] 董家鸿, 张琳, 冯晓彬. 精准外科范式引导下的肝癌介入放射治疗新理念和新技术[J]. 中国实用外科杂志, 2024, 44(9): 988-991, 995.
[9] 田亚, 曹洪庆, 赵德贞. 钇[~(90)Y] 微球放射栓塞治疗在中晚期肝细胞癌中的临床应用[J]. 中国现代医药杂志, 2024, 26(1): 101-106.
[10] SALEM R, JOHNSON GE, KIM E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study[J]. Hepatology, 2021, 74(5): 2342-2352.
[11] DHONDT E, LAMBERT B, HERMIE L, et al. (90)Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial[J]. Radiology, 2022, 303(3): 699-710.
[12] CHOW PKH, GANDHI M, TAN SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma[J]. J Clin Oncol, 2018, 36(19): 1913-1921.
[13] AGIRREZABAL I, BOUATTOUR M, PINATO DJ, et al. Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: a matching-adjusted indirect comparison[J]. Eur J Cancer, 2024, 196: 113427.
[14] D'ALESSIO A, FULGENZI CAM, NISHIDA N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study[J]. Hepatology, 2022, 76(4): 1000-1012.
[15] PONNIAH SA, ZORI AG, CABRERA R. Locoregional therapies for bridging and downstaging hepatocellular carcinoma prior to liver transplant[J]. 2021: 127-143.
[16] GABR A, KULIK L, MOULI S, et al. Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort[J]. Hepatology, 2021, 73(3): 998-1010.
[17] ALISEDA D, MARTÍ-CRUCHAGA P, ZOZAYA G, et al. Liver resection and transplantation following yttrium-90 radioembolization for primary malignant liver tumors: a 15-year single-center experience[J]. Cancers, 2023, 15(3): 733.
[18] SALEM R, KWONG AJ, KIM N, et al. Yttrium-90 radioembolization has become the most utilized bridging treatment for liver transplant candidates in the United States[J]. J Vasc Interv Radiol, 2025, 36(2): 362-363.
[19] FENTON SE, KIRCHER SM, MULCAHY MF, et al. A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in patients with advanced hepatocellular cancer[J]. J Clin Oncol, 2021, 39(15_suppl): e16183.
[20] BIN LEE Y, NAM JY, CHO EJ, et al. A phase I/IIa trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma[J]. Clin Cancer Res, 2023, 29(18): 3650-3658.
[21] YU S, YU MG, KEANE B, et al. A pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma[J]. Oncologist, 2024, 29(3): 270-e413.
[22] MAHVASH A, MURTHY R, ODISIO BC, et al. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2016, 3: 1-7.
[23] ÖCAL O, SCHÜTTE K, ZECH CJ, et al. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib[J]. Eur J Nucl Med Mol Imaging, 2022, 49(13): 4716-4726.
[24] DI FEDERICO A, RIZZO A, CARLONI R, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials[J]. Expert Opin Investig Drugs, 2022, 31(4): 361-369.
[25] VILLALOBOS A, DABBOUS HH, LITTLE O, et al. Safety and efficacy of concurrent atezolizumab/bevacizumab or nivolumab combination therapy with yttrium-90 radioembolization of advanced unresectable hepatocellular carcinoma[J]. Curr Oncol, 2023, 30(12): 10100-10110.
[26] ŞENER N, YAKUPOĞLU A. Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement[J]. Medicine, 2023, 102(35): e34674.
[27] MAZZAFERRO V, SPOSITO C, BHOORI S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study[J]. Hepatology, 2013, 57(5): 1826-1837.
[28] NAM H, YANG H, CHUN HS, et al. Impact of low skeletal muscle mass on long-term outcomes in hepatocellular carcinoma treated with trans-arterial radioembolization: a retrospective multi-center study[J]. Cancers, 2023, 15(21): 5195.
[29] SALEM R, LEWANDOWSKI RJ, MULCAHY MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes[J]. Gastroenterology, 2010, 138(1): 52-64.
[30] MEYER C, PIEPER CC, AHMADZADEHFAR H, et al. Yttrium-90 radioembolization of unresectable hepatocellular carcinoma-a single center experience[J]. Onco Targets Ther, 2017, 10: 4773-4785.
[31] SARWAR A, MALIK MS, VO NH, et al. Efficacy and safety of radiation segmentectomy with (90)Y resin microspheres for hepatocellular carcinoma[J]. Radiology, 2024, 311(2): e231386.
[32] HERMANN AL, DIEUDONNÉ A, RONOT M, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study[J]. Radiology, 2020, 296(3): 673-684.
[33] LEVILLAIN H, BAGNI O, DEROOSE CM, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres[J]. Eur J Nucl Med Mol Imaging, 2021, 48(5): 1570-1584.
[34] GARIN E, TSELIKAS L, GUIU B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(1): 17-29.
[35] CHEN YC, KUO MH, HSU CS, et al. Impact of low muscle mass on hepatocellular carcinoma patients undergoing transcatheter liver-directed therapies: systematic review & meta-analysis[J]. Cancers, 2024, 16(2): 319.
[36] GESCHWIND JFH, SALEM R, CARR BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma[J]. Gastroenterology, 2004, 127(5 Suppl 1): S194-S205.
[37] 张志生, 孔庆利, 梁志鹏. 不同AFP水平肝细胞癌患者手术后5年生存期比较的回顾性分析[J]. 肝脏, 2020, 25(8): 813-815.
[38] EKMEKCIOGLU O, TABAKCI ON, BOZDAG KAPLAN N, et al. Factors affecting the response to treatment and survival in hepatocellular carcinoma patients treated with transarterial radioembolisation: a single-centre experience[J]. Eur J Gastroenterol Hepatol, 2021, 33(6): 926-931.
[39] CHOI JW, KIM HC. Radioembolization for hepatocellular carcinoma: what clinicians need to know[J]. J Liver Cancer, 2022, 22(1): 4-13.
[40] VILLALOBOS A, ARNDT L, CHENG B, et al. Yttrium-90 radiation segmentectomy of hepatocellular carcinoma: a comparative study of the effectiveness, safety, and dosimetry of glass-based versus resin-based microspheres[J]. J Vasc Interv Radiol, 2023, 34(7): 1226-1234.
[41] TURAN BS, BOZKURT MF, ELDEM G, et al. Comparing laboratory toxicity of selective intra-arterial radionuclide therapy for primary and metastatic liver tumors: resin versus glass microspheres[J]. Ann Nucl Med, 2025, 39(4): 373-379.
[42] MORENO LLE, YANG JD, SANCHEZ W, et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2013, 36(3): 714-723.
[43] KOLLIGS F, ARNOLD D, GOLFIERI R, et al. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study[J]. JHEP Rep, 2022, 5(2): 100633.
[44] SALEM R, PADIA SA, LAM M, et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group[J]. Eur J Nucl Med Mol Imaging, 2023, 50(2): 328-343.
[45] VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462.
[46] MUGLIA R, DE GIORGIO M, MARRA P, et al. Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging, 2025, 52(9): 3114-3124.
[47] LEE RC, LIANG PC, LIANG HL, et al. Multicenter evaluation of the safety and efficacy of selective internal radiation therapy with yttrium-90 resin microspheres in Taiwan: data from the RESIN registry[J]. J Gastroenterol Hepatol, 2024, 39(7): 1318-1327.
[48] SANGRO B, CARPANESE L, CIANNI R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation[J]. Hepatology, 2011, 54(3): 868-878.
[49] SANAI FM, ALZANBAGI A, ARABI M, et al. Transarterial chemoembolization outperforms radioembolization in early- and intermediate-stage hepatocellular carcinoma: a multicenter retrospective study[J]. Cancers, 2025, 17(13): 2254.

基金资助

白求恩耀动神州-药学科研能力建设基金资助项目(Z04JKM2023E040)